Charlotte Lanteri's research while affiliated with Uniformed Services University of the Health Sciences and other places

... Their results pointed to three distinct inflammatory biomarker patterns that could stratify a heterogeneous population and that were associated with comorbid diseases and illness severity of those patients. This exploratory step gave important insights regarding the inclusion of biomarkers in the definition of clinical phenotypes, suggesting that these could be used for a personalized approach to the triage of care and therapeutic indications [27]. ...

... Activity against blood-stage parasites is thought to be independent of CYP-2D6 metabolism, potentially involving interference with heme polymerization, or oxidative mechanisms [36]. The 5,6-orthoquinone Any AE metabolite of primaquine is considered a surrogate marker for active metabolites of primaquine [37]. Although we measured the 5,6-orthoquinone metabolite of tafenoquine, a relationship between its concentration and parasite killing was not observed. ...

... Globally, COVID-19 is associated with significant clinical, public health and economic burden, leading to missed school and work to recover from illness [7,8]. Patient-reported outcomes (PROs) are important in order to fully capture the symptom burden of COVID-19 and assess the effectiveness of treatments [9]. Epidemiological studies show viral respiratory diseases share similar symptom profiles, including fever/chills, cough, shortness of breath, fatigue, sore throat, muscle pain or body aches, headache, vomiting, and diarrhea [10]. ...

... The CVIET haplotype is predominant in many African [21,32] and Southeast Asian countries in which CQ has been withdrawn for at least ten years after [33][34][35]; however, it has also been observed in P. falciparum parasites from South America [36], while SVMNT is dominant in South America and Oceania [37]. In Brazil, the CVIET haplotype was rarely encountered (it was found in only one sample from the municipality of Manaus), as previously seen in isolates from Amazonas and Rondônia [38]. ...

... For the antibody binding assay used for screening at enrollment, serum samples were diluted 1:400 and 1:8000 and screened for immunoglobulin G (IgG) reactivity with SARS-CoV-2 spike protein and nucleocapsid protein (N), and four human coronavirus (HCoV) spike proteins using a multiplex microsphere-based immunoassay, as previously described. 54 Post-infection sera from the EPICC study The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a cohort study of U.S. Military Health System (MHS) beneficiaries that includes enrollment and longitudinal follow up of those with a history of SARS-CoV-2 infection. 55 Eligibility criteria for enrollment included presenting to clinical care with COVID-19-like illness and being tested for SARS-CoV-2 by polymerase chain reaction (PCR) assay (See Tables S1A and S1B). ...

... None of these particular codons could be identified in any of the samples. We did not test for plasmepsin gene amplification in light of the exceptions to its putative association with PPQ resistance that have been reported from genetic experiments and field samples in Southeast Asia and Africa [42][43][44][45]. ...

... These assays use pathogen-specific antigens covalently bonded to fluorophore-loaded carboxyl beads, facilitating simultaneous identification of multiple pathogen-specific antibodies. MMIAs have been used to detect and differentiate antibodies against viral infections such as human herpesviruses and flaviviruses (e.g., Epstein-Barr, West Nile, Zika, and dengue viruses) (25,26), used to identify SARS-CoV-2 IgG seroconversion (27)(28)(29)(30) and proposed for public health use since the early 2000s (31,32). ...